Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus NEXPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus NEXPLANON.
ASHLYNA vs NEXPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Category C
Category C
Contraceptive
Contraceptive